Triple Analysis: Colorectal Cancer, Angiogenesis and Protein Kinase Inhibitors
BioSeeker Group AB
January 30, 2012 4202 Pages - SKU: BIOS6796105
|
|
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.
Below is a short synopsis of eachPart Included in this report:
Part I: Colorectal Cancer
The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.
This Part Is based on the following publication:
A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market
Part II: Angiogenesis
The angiogenesis report part comprises defined and up to date development strategies for 239 drugs affecting angiogenesis in oncology within the portfolio of 148 investigators, from Preclinical to Marketed. This report part extensively analyses 174 identified targets of angiogenesis affecting drugs, organized into 167 drug target strategies, and assesses them in 64 different cancer indications.
This Part Is based on the following publication:
Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline
Part III: Protein Kinase Inhibitors
The protein kinase report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. This report part extensively analyses 133 identified targets of protein kinase drugs, organized into 200 drug target strategies, and assesses them in 57 different cancer indications.This Part Is based on the following publication:
Protein Kinase Therapeutics in Oncology - Where to Commercialize?
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:- Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
- Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
- Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area strategies
- Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.
|
- Key Topics Covered:
- Part I: Colorectal Cancer
- 5.1 The Scope of this Report 28
- 6 Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets) 32-451
- 7 Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs) 452-699
- 8 Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-745
- 9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies) 746-1,039
- 10 Disclaimer 1040
- 11 Drug Index 1041
- 12 Company Index 1050
- Figures: Includes 6 Figures
- Tables: Includes 242 Tables
- Total Number of Pages: 1,056
- Part II: Angiogenesis
- 5.1 The Scope of this Report 37
- 6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
- 7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
- 8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
- 9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
- 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
- 12 Drug Index 1687
- 13 Company Index 1697
- Figures: Includes 7 Figures
- Tables: Includes 310 Tables
- Total Number of Pages: 1,704
- Part III: Protein Kinase Inhibitors
- 5.1 The Scope of this Report 30
- 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (133 Drug Targets) 36-336
- 7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Protein Kinase Therapeutic Pipeline? (200 Drug Target Strategies and 409 Drugs) 337-407
- 8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Drugs in Oncology by Compound Type (7 Compound Strategies) 408-495
- 9 Selecting Cancer Indications for Protein Kinase Therapeutics (57 Different Cancer Indications) 496-649
- 10 Portfolio Planning: Competitive Benchmarking of Protein Kinase Cancer Therapeutic Pipeline by Investigator (160 Investigators) 650-1417
- 12 Drug Index 1419
- 13 Company Index 1433
- Figures: Includes 6 Figures
- Tables: Includes 302 Tables
- Total Number of Pages: 1442
Share this report
Other tasks Related Markets Oncology/Hematology Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
